Medical and Science
Beyond the protocol: How Icon Group is redefining clinical trials with heart

Sophie Mepham, Group Executive Manager of Research at Icon Group, invites us into the often unseen world where purpose and possibility collide in clinical trials. With Clinical Trials Day (20 May) theme of Powered by Purpose, she reflects on her deeply personal connection with clinical trials.
In this Health Industry Hub podcast, Mepham opens the door to Icon Group’s landscape of clinical research. For her, purpose is the pulse behind every study, every patient enrolled, every step taken toward new treatments.
Central to the discussion is the delicate dance involved in securing funding that keeps clinical trials moving forward without ever losing sight of the patients it aims to serve. Mepham speaks to the challenges of truly bringing the diverse patient voice into the heart of clinical trials, and the need to widen the lens so the research reflects the real-world complexities faced by patients.
The conversation also touches on the economic footprint of clinical trials in Australia. Mepham acknowledges the tension between local trial realities and the demands of global studies, raising questions about what Australia must do to remain competitive in the R&D landscape.
Peering into the future, Mepham shares key trends shaping clinical trials, a shift toward more adaptive, technology-driven trials, where data and patient experience converge in new ways. It is an evolving story of possibility, one that promises to reshape oncology research in ways we’ve only begun to imagine.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Biotechnology

NRF backs local ophthalmic biotech
A Melbourne-based biotechnology company has landed a game-changing investment to push forward its novel glaucoma implant to address the long-standing […]
MoreNews & Trends - MedTech & Diagnostics

Who’s accountable for Australia’s private hospital meltdown?
Private hospitals across Australia are facing an unprecedented viability crisis, one that healthcare leaders say has been worsened by profit-hungry […]
MoreNews & Trends - MedTech & Diagnostics

Medicare-funded lifeline fuels community action in cardiovascular disease
With the Medicare-funded Heart Health Check extension set to begin on 1 July 2025, advocates are recognising the significance of […]
MoreNews & Trends - Pharmaceuticals

Growth hormone therapy gains TGA nod
The Therapeutic Goods Administration (TGA) has approved a new growth hormone deficiency (GHD) treatment for children and adolescents, expanding options […]
More